Oct. 24 at 11:36 PM
$VSTM
Verastem Oncology (VSTM) - Q3 2025 Overview and Key Upcoming Q4 Catalysts:
The second-quarter Form 10-Q (filed August 7, 2025) outlined multiple milestones expected in the second half of 2025.
While Q3 will primarily reflect early U.S. launch revenue from AVMAPKI (avutometinib + defactinib), expected to land around US
$6–8 million, and steady progress in the VS-7375 KRAS G12D program, four major updates remain pending for Q4 2025 that could significantly influence both sentiment and valuation.